Marketed drugs used for the management of hypercholesterolemia as anticancer armament

References

• SimpsonCBJamesJCThe efficacy of mitomycin-C in the treatment of laryngotracheal stenosisLaryngoscope2006116101923192517003706
   PubMedGoogle Scholar
• MearzaAAAslanidesIMUses and complications of mitomycin C in ophthalmologyExpert Opin Drug Saf200761273217181449
   PubMed Web of Science ®Google Scholar
• LuYLiuXFLiuTRCelecoxib exerts antitumor effects in HL-60 acute leukemia cells and inhibits autophagy by affecting lysosome functionBiomed Pharmacother2016841551155727884749
   PubMedGoogle Scholar
• Vila-LeaheyAOldfordSAMarignaniPAWangJHaidlIDMarshallJSRanitidine modifies myeloid cell populations and inhibits breast tumor development and spread in miceOncoimmunology201657e115159127622015
   PubMedGoogle Scholar
• CharlesEHammadiMKischelPThe antidepressant fluoxetine induces necrosis by energy depletion and mitochondrial calcium overloadOncotarget2017823181319627911858
   PubMedGoogle Scholar
• LiJLiuJLiangZSimvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growthCell Death Dis201783e2673
   PubMedGoogle Scholar
• PapanagnouPStivarouTTsironiMUnexploited antineoplastic effects of commercially available anti-diabetic drugsPharmaceuticals (Basel)201692
   PubMedGoogle Scholar
• EricesRCubillosSAravenaRDiabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progressionOncotarget2017813208652088028209916
   PubMedGoogle Scholar
• PapanagnouPBaltopoulosPTsironiMMarketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists’ arsenalTher Clin Risk Manag20151180781926056460
   PubMed Web of Science ®Google Scholar
• JensenKBikasAPatelANelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cellsEndocr Relat Cancer201724314715628137980
   PubMedGoogle Scholar
• RussoAPellosiDSPagliaraVBiotin-targeted Pluronic(®) P123/F127 mixed micelles delivering niclosamide: A repositioning strategy to treat drug-resistant lung cancer cellsInt J Pharm2016511112713927374195
   PubMedGoogle Scholar
• AhnSYYangJHKimNHAnti-helminthic niclosamide inhibits Ras-driven oncogenic transformation via activation of GSK-3Oncotarget2017819318563186328418865
   PubMedGoogle Scholar
• MeiZLiangMLiLZhangYWangQYangWEffects of statins on cancer mortality and progression: A systematic review and meta-analysis of 95 cohorts including 1,111,407 individualsInt J Cancer201714051068108127859151
   PubMed Web of Science ®Google Scholar
• CaiXHuXTanXMetformin induced AMPK activation, G0/G1 Phase cell cycle arrest and the inhibition of growth of esophageal squamous cell carcinomas in vitro and in vivoPLoS One2015107e013334926196392
   PubMed Web of Science ®Google Scholar
• WeberCNoelsHAtherosclerosis: current pathogenesis and therapeutic optionsNat Med201117111410142222064431
   PubMed Web of Science ®Google Scholar
• PeltonKCoticchiaCMCuratoloASHypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivoAm J Pathol201418472099211024952430
   PubMedGoogle Scholar
• FarnierMChenEJohnson-LevonasAOMcCrary SiskCMitchelYBEffects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemiaVasc Health Risk Manag20141027929024855368
   PubMedGoogle Scholar
• ItzhakiOGreenbergEShalmonBNicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanomaPLoS One201382e5716023451174
   PubMed Web of Science ®Google Scholar
• ElangovanSPathaniaRRamachandranSThe niacin/butyrate receptor GPR109A suppresses mammary tumorigenesis by inhibiting cell survivalCancer Res20147441166117824371223
   PubMed Web of Science ®Google Scholar
• GaoJLiaoJYangGYCAAX-box protein, prenylation process and carcinogenesisAm J Transl Res20091331232519956441
   PubMedGoogle Scholar
• SchoolingCMAu YeungSLFreemanGCowlingBJThe effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trialsBMC Med2013115723448151
   PubMed Web of Science ®Google Scholar
• SolomonKRPeltonKBoucherKEzetimibe is an inhibitor of tumor angiogenesisAm J Pathol200917431017102619179610
   PubMedGoogle Scholar
• YuCCLaiWTShihKCEfficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trialBMC Res Notes2012525122621316
   PubMedGoogle Scholar
• ZhaoZCaoXPanYShaSZhaoTZhangTSimvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cellsOncol Res2012205–618719523581225
   PubMedGoogle Scholar
• ShangLJiaSSJiangHMWangHXuWHLvCJSimvastatin downregulates expression of TGF-betaRII and inhibits proliferation of A549 cells via ERKTumour Biol20153664819482425631750
   PubMedGoogle Scholar
• WilliamsABLiLNguyenBBrownPLevisMSmallDFluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemiaBlood2012120153069307922927251
   PubMed Web of Science ®Google Scholar
• MiraECarmona-RodriguezLTardaguilaMA lovastatin-elicited genetic program inhibits M2 macrophage polarization and enhances T cell infiltration into spontaneous mouse mammary tumorsOncotarget20134122288230124317954
   PubMedGoogle Scholar
• LiaoJChungYTYangALAtorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre miceMol Carcinog201352973975022549877
   PubMed Web of Science ®Google Scholar
• XuPYuHZhangZHydrogen-bonded and reduction-responsive micelles loading atorvastatin for therapy of breast cancer metastasisBiomaterials201435267574758724899527
   PubMed Web of Science ®Google Scholar
• MatusewiczLMeissnerJToporkiewiczMSikorskiAFThe effect of statins on cancer cells–reviewTumour Biol20153674889490426002574
   PubMedGoogle Scholar
• LiuHWangZLiYLiWChenYSimvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivoNeoplasma201360324024623373992
   PubMed Web of Science ®Google Scholar
• WangLYangHLeiZRepression of TIF1gamma by SOX2 promotes TGF-beta-induced epithelial-mesenchymal transition in non-small-cell lung cancerOncogene201635786787725961934
   PubMed Web of Science ®Google Scholar
• LiYFuJYuanXHuCSimvastatin inhibits the proliferation of A549 lung cancer cells through oxidative stress and up-regulation of SOD2Die Pharmazie201469861061425158572
   PubMedGoogle Scholar
• YuXPanYMaHLiWSimvastatin inhibits proliferation and induces apoptosis in human lung cancer cellsOncol Res201320835135723924855
   PubMed Web of Science ®Google Scholar
• LiangYWChangCCHungCMChenTYHuangTYHsuYCPreclinical activity of simvastatin induces cell cycle arrest in G1 via blockade of cyclin D-Cdk4 expression in Non-Small Cell Lung Cancer (NSCLC)Int J Mol Sci20131435806581623481641
   PubMed Web of Science ®Google Scholar
• SpampanatoCDe MariaSSarnataroMSimvastatin inhibits cancer cell growth by inducing apoptosis correlated to activation of Bax and down-regulation of BCL-2 gene expressionInt J Oncol201240493594122134829
   PubMed Web of Science ®Google Scholar
• Ghosh-ChoudhuryNMandalCCGhosh-ChoudhuryNGhosh ChoudhuryGSimvastatin induces derepression of PTEN expression via NFkappaB to inhibit breast cancer cell growthCell Signal201022574975820060890
   PubMed Web of Science ®Google Scholar
• MandalCCGhosh-ChoudhuryNYonedaTChoudhuryGGGhosh-ChoudhuryNSimvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44J Biol Chem201128613113141132721199873
   PubMed Web of Science ®Google Scholar
• WangZWuYWangHInterplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motilityProc Natl Acad Sci U S A20141111E89E9824367099
   PubMed Web of Science ®Google Scholar
• KotamrajuSWilliamsCLKalyanaramanBStatin-induced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathwaysCancer Res200767157386739417671209
   PubMed Web of Science ®Google Scholar
• EinbondLSWuHASanduCDigitoxin enhances the growth inhibitory effects of thapsigargin and simvastatin on ER negative human breast cancer cellsFitoterapia201610914615426691294
   PubMedGoogle Scholar
• LiangZLiWLiuJSimvastatin suppresses the DNA replication licensing factor MCM7 and inhibits the growth of tamoxifen-resistant breast cancer cellsSci Rep201774177628150753
   PubMed Web of Science ®Google Scholar
• LehnSFernoMJirstromKRydenLLandbergGA non-functional retinoblastoma tumor suppressor (RB) pathway in premenopausal breast cancer is associated with resistance to tamoxifenCell Cycle201110695696221358261
   PubMed Web of Science ®Google Scholar
• RogersMKalraSMoukharskayaJSynergistic growth inhibition of PC3 prostate cancer cells with low-dose combinations of simvastatin and alendronateAnticancer Res20153541851185925862838
   PubMedGoogle Scholar
• NordstrandALundholmMLarssonALernerUHWidmarkAWikstromPInhibition of the insulin-like growth factor-1 receptor enhances effects of simvastatin on prostate cancer cells in co-culture with boneCancer Microenviron20136323124023335094
   PubMedGoogle Scholar
• Al-HuseinBGocASomanathPRSuppression of interactions between prostate tumor cell-surface integrin and endothelial ICAM-1 by simvastatin inhibits micrometastasisJ Cell Physiol2013228112139214823559257
   PubMedGoogle Scholar
• WangGCaoRWangYSimvastatin induces cell cycle arrest and inhibits proliferation of bladder cancer cells via PPARgamma signalling pathwaySci Rep201663578327779188
   PubMed Web of Science ®Google Scholar
• BorahayMAKilicGSYallampalliCSimvastatin potently induces calcium-dependent apoptosis of human leiomyoma cellsJ Biol Chem201428951350753508625359773
   PubMed Web of Science ®Google Scholar
• ChoSJKimJSKimJMLeeJYJungHCSongISSimvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in miceInt J Cancer2008123495195718521906
   PubMedGoogle Scholar
• JangHJHongEMParkSWStatin induces apoptosis of human colon cancer cells and downregulation of insulin-like growth factor 1 receptor via proapoptotic ERK activationOncol Lett201612125025627347133
   PubMedGoogle Scholar
• de LlobetLIBaroMMesiaRBalartJSimvastatin enhances the effects of radiotherapy and cetuximab on a cell line (FaDu) derived from a squamous cell carcinoma of head and neckTransl Oncol20147451352225171892
   PubMedGoogle Scholar
• FuchsDBergesCOpelzGDanielVNaujokatCHMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathwayBiochem Biophys Res Commun2008374230931418625202
   PubMedGoogle Scholar
• SaitoASaitoNMolWSimvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cellsMelanoma Res2008182859418337644
   PubMed Web of Science ®Google Scholar
• GlynnSAO’SullivanDEustaceAJClynesMO’DonovanNThe 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsBMC Cancer20088918199328
   PubMed Web of Science ®Google Scholar
• GronichNDruckerLShapiroHRadnayJYarkoniSLishnerMSimvastatin induces death of multiple myeloma cell linesJ Investig Med2004525335344
   PubMedGoogle Scholar
• SchmidmaierRBaumannPSimsekMDayyaniFEmmerichBMeinhardtGThe HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinaseBlood200410461825183215161667
   PubMedGoogle Scholar
• AtilBBerger-SieczkowskiEBardyJWernerMHoheneggerMIn vitro and in vivo downregulation of the ATP binding cassette transporter B1 by the HMG-CoA reductase inhibitor simvastatinNaunyn Schmiedeberg’s Arch Pharmacol20163891173226319048
   PubMedGoogle Scholar
• WolfeARDebebBGLacerdaLSimvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3aBreast Cancer Res Treat2015154349550826590814
   PubMedGoogle Scholar
• FangZTangYFangJSimvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathwayPLoS One201385e6282323690956
   PubMed Web of Science ®Google Scholar
• AlupeiMCLicareteEPatrasLBanciuMLiposomal simvastatin inhibits tumor growth via targeting tumor-associated macrophages-mediated oxidative stressCancer Lett20153562 Pt B94695225444912
   PubMed Web of Science ®Google Scholar
• CoimbraMBanciuMFensMHLiposomal pravastatin inhibits tumor growth by targeting cancer-related inflammationJ Control Release2010148330331020869410
   PubMed Web of Science ®Google Scholar
• LeeSJLeeILeeJParkCKangWKStatins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90alpha in human colorectal cancerBr J Cancer2014111349750524945998
   PubMed Web of Science ®Google Scholar
• LiGZhengJXuBLingJQiuWWangYSimvastatin inhibits tumor angiogenesis in HER2-overexpressing human colorectal cancerBiomed Pharmacother20178541842427887848
   PubMed Web of Science ®Google Scholar
• CohenJIHMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphomaBr J Cancer20059291593159815856040
   PubMedGoogle Scholar
• InanoHSuzukiKOnodaMWakabayashiKAnti-carcinogenic activity of simvastatin during the promotion phase of radiation-induced mammary tumorigenesis of ratsCarcinogenesis1997189172317279328167
   PubMed Web of Science ®Google Scholar
• ClutterbuckRDMillarBCPowlesRLInhibitory effect of simvastatin on the proliferation of human myeloid leukaemia cells in severe combined immunodeficient (SCID) miceBr J Haematol199810225225279695968
   PubMed Web of Science ®Google Scholar
• ErbasHBalOCakirEEffect of rosuvastatin on arginase enzyme activity and polyamine production in experimental breast cancerBalkan Med J2015321899525759778
   PubMedGoogle Scholar
• PolatMFTaysiSPolatSBoyukABakanEElevated serum arginase activity levels in patients with breast cancerSurg Today200333965566112928840
   PubMedGoogle Scholar
• MorrisSMJrArginine metabolism: boundaries of our knowledgeJ Nutr20071376 Suppl 21602s1609s17513435
   PubMed Web of Science ®Google Scholar
• NowotarskiSLWosterPMCaseroRAJrPolyamines and cancer: implications for chemotherapy and chemopreventionExpert Rev Mol Med201315e323432971
   PubMed Web of Science ®Google Scholar
• PlunkettWArginine addiction in AMLBlood2015125263971397226113532
   PubMedGoogle Scholar
• NarisawaTFukauraYTanidaNHasebeMItoMAizawaRChemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR miceTohoku J Exp Med199618021311389111762
   PubMedGoogle Scholar
• NarisawaTMorotomiMFukauraYHasebeMItoMAizawaRChemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 ratsJpn J Cancer Res19968787988048797885
   PubMedGoogle Scholar
• ShellmanYGRibbleDMillerLLovastatin-induced apoptosis in human melanoma cell linesMelanoma Res2005152838915846140
   PubMed Web of Science ®Google Scholar
• DimitroulakosJYegerHHMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cellsNat Med1996233263338612233
   PubMedGoogle Scholar
• RubinsJBGreatensTKratzkeRATanATPolunovskyVABittermanPLovastatin induces apoptosis in malignant mesothelioma cellsAm J Respir Crit Care Med19981575 Pt 1161616229603146
   PubMedGoogle Scholar
• DimitroulakosJNohynekDBackwayKLIncreased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approachBlood1999934130813189949174
   PubMed Web of Science ®Google Scholar
• MacaulayRJWangWDimitroulakosJBeckerLEYegerHLovastatin-induced apoptosis of human medulloblastoma cell lines in vitroJ Neurooncol199942111110360474
   PubMedGoogle Scholar
• DimitroulakosJYeLYBenzaquenMDifferential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implicationsClin Cancer Res20017115816711205904
   PubMedGoogle Scholar
• OgunwobiOOBealesILStatins inhibit proliferation and induce apoptosis in Barrett’s esophageal adenocarcinoma cellsAm J Gastroenterol2008103482583718371146
   PubMed Web of Science ®Google Scholar
• MaksimovaEYieTARomWNIn vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agentLung20081861455418034278
   PubMed Web of Science ®Google Scholar
• ParkIHKimJYJungJIHanJYLovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutationsInvest New Drugs201028679179919760159
   PubMed Web of Science ®Google Scholar
• JeonJHKimSKKimHJChangJAhnCMChangYSLipid raft modulation inhibits NSCLC cell migration through delocalization of the focal adhesion complexLung Cancer201069216517119945766
   PubMed Web of Science ®Google Scholar
• ZhangXTengYYangFMCM2 is a therapeutic target of lovastatin in human non-small cell lung carcinomasOncol Rep20153352599260525738322
   PubMed Web of Science ®Google Scholar
• AgarwalBBhendwalSHalmosBMossSFRameyWGHoltPRLovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cellsClin Cancer Res1999582223222910473109
   PubMed Web of Science ®Google Scholar
• SwamyMVCoomaIReddyBSRaoCVLamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: a novel approach in developing effective chemopreventive regimensInt J Oncol200220475375911894121
   PubMedGoogle Scholar
• ManthaAJHansonJEGossGLagardeAELorimerIADimitroulakosJTargeting the mevalonate pathway inhibits the function of the epidermal growth factor receptorClin Cancer Res20051162398240715788691
   PubMed Web of Science ®Google Scholar
• HoqueAChenHXuXCStatin induces apoptosis and cell growth arrest in prostate cancer cellsCancer Epidemiol Biomarkers Prev2008171889418199714
   PubMed Web of Science ®Google Scholar
• ParkCLeeIKangWKLovastatin-induced E2F-1 modulation and its effect on prostate cancer cell deathCarcinogenesis200122101727173111577016
   PubMed Web of Science ®Google Scholar
• AfshordelSKernBClasohmJLovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation – impact of Ras-/Rho-prenylationPharmacol Res201591697725497898
   PubMed Web of Science ®Google Scholar
• Glodkowska-MrowkaEMrowkaPBasakGWStatins inhibit ABCB1 and ABCG2 drug transporter activity in chronic myeloid leukemia cells and potentiate antileukemic effects of imatinibExp Hematol201442643944724667683
   PubMedGoogle Scholar
• SongXLiuBCLuXYLovastatin inhibits human B lymphoma cell proliferation by reducing intracellular ROS and TRPC6 expressionBiochim Biophys Acta20141843589490124518247
   PubMed Web of Science ®Google Scholar
• YangTYaoHHeGEffects of lovastatin on MDA-MB-231 breast cancer cells: an antibody microarray analysisJ Cancer20167219219926819643
   PubMedGoogle Scholar
• HolsteinSAHohlRJInteraction of cytosine arabinoside and lovastatin in human leukemia cellsLeuk Res200125865166011397469
   PubMedGoogle Scholar
• ZhaoTTLe FrancoisBGGossGDingKBradburyPADimitroulakosJLovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteinsOncogene201029334682469220562912
   PubMedGoogle Scholar
• WeitbergABThe antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer preventionJ Exp Clin Cancer Res200726458358618365556
   PubMedGoogle Scholar
• AjithTASojaMA comparative study on the antimutagenicity of atorvastatin and lovastatin against directly acting mutagensCell Biol Toxicol200622426927416642263
   PubMedGoogle Scholar
• FeleszkoWZagozdzonRGolabJJakobisiakMPotentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in miceEur J Cancer19983434064119640231
   PubMedGoogle Scholar
• FeleszkoWBalkowiecEZSieberthELovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesisInt J Cancer199981456056710225445
   PubMed Web of Science ®Google Scholar
• AjithTAHarikumarKBThasnaHSabuMCBabithaNVProapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton’s lymphoma ascites tumor in miceClin Chim Acta20063661–232232816380106
   PubMedGoogle Scholar
• MatarPRozadosVRRoggeroEAScharovskyOGLovastatin inhibits tumor growth and metastasis development of a rat fibrosarcomaCancer Biother Radiopharm199813538739310851430
   PubMedGoogle Scholar
• MatarPRozadosVRBindaMMRoggeroEABonfilRDScharovskyOGInhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphomaClin Exp Metastasis1999171192510390143
   PubMedGoogle Scholar
• JaniJPSpechtSStemmlerNMetastasis of B16F10 mouse melanoma inhibited by lovastatin, an inhibitor of cholesterol biosynthesisInvasion Metastasis19931363143247860224
   PubMedGoogle Scholar
• AloPLViscaPMarciAMangoniABottiCDi TondoUExpression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patientsCancer19967734744828630954
   PubMed Web of Science ®Google Scholar
• HawkMACesenKTSiglinJCStonerGDRuchRJInhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatinCancer Lett19961091–22172229020924
   PubMed Web of Science ®Google Scholar
• DingNCuiXXGaoZA triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumorsInt J Oncol20144462139214524647860
   PubMedGoogle Scholar
• IslamMSharmaSKumarBTeknosTNAtorvastatin inhibits RhoC function and limits head and neck cancer metastasisOral Oncol201349877878623648017
   PubMed Web of Science ®Google Scholar
• FanZJiangHWangZQuJAtorvastatin partially inhibits the epithelial-mesenchymal transition in A549 cells induced by TGF-beta1 by attenuating the upregulation of SphK1Oncol Rep20163621016102227349500
   PubMed Web of Science ®Google Scholar
• GhalaliAWiklundFZhengHSteniusUHogbergJAtorvastatin prevents ATP-driven invasiveness via P2X7 and EHBP1 signaling in PTEN-expressing prostate cancer cellsCarcinogenesis20143571547155524451147
   PubMedGoogle Scholar
• AldertonGKTumour immunology: suppressing tumorigenic inflammationNat Rev Cancer2012124228
   PubMedGoogle Scholar
• BrisoEMGuinea-ViniegraJBakiriLInflammation-mediated skin tumorigenesis induced by epidermal c-FosGenes Dev201327181959197324029918
   PubMedGoogle Scholar
• SuhNReddyBSDeCastroACombination of atorvastatin with sulindac or naproxen profoundly inhibits colonic adenocarcinomas by suppressing the p65/beta-catenin/cyclin D1 signaling pathway in ratsCancer Prev Res (Phila)20114111895190221764859
   PubMed Web of Science ®Google Scholar
• ZhengXCuiXXAvilaGEAtorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient miceClin Cancer Res20071318 Pt 15480548717875778
   PubMedGoogle Scholar
• ZhengXCuiXXGaoZAtorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceCancer Prev Res (Phila)20103111412420051379
   PubMedGoogle Scholar
• SwamyMVPatlollaJMSteeleVEKopelovichLReddyBSRaoCVChemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin miceCancer Res200666147370737716849589
   PubMed Web of Science ®Google Scholar
• ShachafCMPerezODYoussefSInhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesisBlood200711072674268417622571
   PubMed Web of Science ®Google Scholar
• Slawinska-BrychAZdzisinskaBKandefer-SzerszenMFluvastatin inhibits growth and alters the malignant phenotype of the C6 glioma cell linePharmacol Rep201466112112924905317
   PubMed Web of Science ®Google Scholar
• SassanoAKatsoulidisEAnticoGSuppressive effects of statins on acute promyelocytic leukemia cellsCancer Res20076794524453217483369
   PubMed Web of Science ®Google Scholar
• WoodardJSassanoAHayNPlataniasLCStatin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinomaClin Cancer Res200814144640464918628479
   PubMed Web of Science ®Google Scholar
• KusamaTMukaiMIwasakiTInhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitorsCancer Res200161124885489111406567
   PubMed Web of Science ®Google Scholar
• TakahashiHKWeitz-SchmidtGIwagakiHYoshinoTTanakaNNishiboriMHypothesis: the antitumor activities of statins may be mediated by IL-18J Leukocyte Biol200680221521616735695
   PubMedGoogle Scholar
• HoriguchiASumitomoMAsakumaJAsanoTAsanoTHayakawaM3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasisClin Cancer Res200410248648865515623649
   PubMed Web of Science ®Google Scholar
• ThibaultASamidDTompkinsACPhase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancerClin Cancer Res1996234834919816194
   PubMedGoogle Scholar
• LarnerJJaneJLawsEPackerRMyersCShaffreyMA phase I–II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiformeAm J Clin Oncol19982165795839856659
   PubMed Web of Science ®Google Scholar
• KimWSKimMMChoiHJPhase II study of high-dose lovastatin in patients with advanced gastric adenocarcinomaInvest New Drugs2001191818311291836
   PubMedGoogle Scholar
• KawataSYamasakiENagaseTEffect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trialBr J Cancer200184788689111286466
   PubMed Web of Science ®Google Scholar
• GrafHJungstCStraubGChemoembolization combined with pravastatin improves survival in patients with hepatocellular carcinomaDigestion2008781343818797167
   PubMed Web of Science ®Google Scholar
• LeeJJungKHParkYSSimvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II studyCancer Chemother Pharmacol200964465766319169686
   PubMed Web of Science ®Google Scholar
• BaasJMKrensLLten TijeAJSafety and efficacy of the addition of simvastatin to cetuximab in previously treated KRAS mutant metastatic colorectal cancer patientsInvest New Drugs20153361242124726386973
   PubMedGoogle Scholar
• BaasJMKrensLLBosMMSafety and efficacy of the addition of simvastatin to panitumumab in previously treated KRAS mutant metastatic colorectal cancer patientsAnticancer Drugs201526887287726053280
   PubMedGoogle Scholar
• KrensLLSimkensLHBaasJMStatin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 studyPLoS One2014911e11220125375154
   PubMedGoogle Scholar
• NielsenSFNordestgaardBGBojesenSEStatin use and reduced cancer-related mortalityN Engl J Med20133686576577
   PubMedGoogle Scholar
• KlopCDriessenJHde VriesFStatin use and reduced cancer-related mortalityN Engl J Med20133686574
   PubMedGoogle Scholar
• KopelEMaorEGoldenbergIStatin use and reduced cancer-related mortalityN Engl J Med2013368657557623388015
   PubMedGoogle Scholar
• BrewerTMMasudaHLiuDDStatin use in primary inflammatory breast cancer: a cohort studyBr J Cancer2013109231832423820253
   PubMed Web of Science ®Google Scholar
• BjarnadottirORomeroQBendahlPOTargeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trialBreast Cancer Res Treat2013138249950823471651
   PubMed Web of Science ®Google Scholar
• BjarnadottirOKimbungSJohanssonIGlobal transcriptional changes following statin treatment in breast cancerClin Cancer Res201521153402341125840970
   PubMedGoogle Scholar
• FeldtMBjarnadottirOKimbungSStatin-induced antiproliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trialJ Transl Med20151313325925673
   PubMedGoogle Scholar
• GarwoodERKumarASBaehnerFLFluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancerBreast Cancer Res Treat2010119113714419728082
   PubMed Web of Science ®Google Scholar
• WangAStefanickMLKapphahnKRelation of statin use with non-melanoma skin cancer: prospective results from the Women’s Health InitiativeBr J Cancer2016114331432026742009
   PubMed Web of Science ®Google Scholar
• Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet19943448934138313897968073
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet2002360932672212114036
   PubMed Web of Science ®Google Scholar
• KuoppalaJLamminpaaAPukkalaEStatins and cancer: a systematic review and meta-analysisEur J Cancer200844152122213218707867
   PubMed Web of Science ®Google Scholar
• ArnspangSPottegardAFriisSStatin use and risk of non-melanoma skin cancer: a nationwide study in DenmarkBr J Cancer2015112115315625290087
   PubMedGoogle Scholar
• BlaisLDesgagneALeLorierJ3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control studyArch Intern Med2000160152363236810927735
   PubMedGoogle Scholar
• GraafMRBeiderbeckABEgbertsACRichelDJGuchelaarHJThe risk of cancer in users of statinsJ Clin Oncol200422122388239415197200
   PubMed Web of Science ®Google Scholar
• PetoREmbersonJLandrayMAnalyses of cancer data from three ezetimibe trialsN Engl J Med2008359131357136618765432
   PubMed Web of Science ®Google Scholar
• BjerreLMLeLorierJDo statins cause cancer? A meta-analysis of large randomized clinical trialsAm J Med2001110971672311403756
   PubMedGoogle Scholar
• AsgariMMTangJEpsteinEHJrStatin use and risk of basal cell carcinomaJ Am Acad Dermatol2009611667219464071
   PubMed Web of Science ®Google Scholar
• HaukkaJSankilaRKlaukkaTIncidence of cancer and statin usage–record linkage studyInt J Cancer2010126127928419739258
   PubMed Web of Science ®Google Scholar
• LiXWuXBChenQStatin use is not associated with reduced risk of skin cancer: a meta-analysisBr J Cancer2014110380280724366301
   PubMed Web of Science ®Google Scholar
• LimSHKimTWHongYSA randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancerBr J Cancer2015113101421142626505681
   PubMedGoogle Scholar
• WallaceAChinnDRubinGTaking simvastatin in the morning compared with in the evening: randomised controlled trialBMJ2003327741878814525878
   PubMedGoogle Scholar
• DrazenJMD’AgostinoRBWareJHMorrisseySCurfmanGDEzetimibe and cancer–an uncertain associationN Engl J Med2008359131398139918765434
   PubMedGoogle Scholar
• RosseboABPedersenTRBomanKIntensive lipid lowering with simvastatin and ezetimibe in aortic stenosisN Engl J Med2008359131343135618765433
   PubMed Web of Science ®Google Scholar
• GreenARameyDREmneusMIncidence of cancer and mortality in patients from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trialAm J Cardiol2014114101518152225267716
   PubMedGoogle Scholar
• MarcelliMCunninghamGRHaidacherSJCaspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaPCancer Res199858176839426061
   PubMed Web of Science ®Google Scholar
• GbelcovaHLenicekMZelenkaJDifferences in antitumor effects of various statins on human pancreatic cancerInt J Cancer200812261214122118027870
   PubMed Web of Science ®Google Scholar
• BurkeLPKukolyCAStatins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hoursLeuk Lymphoma200849232233018231920
   PubMed Web of Science ®Google Scholar
• PrasannaPThibaultALiuLSamidDLipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cellsJ Neurochem19966627107168592143
   PubMed Web of Science ®Google Scholar
• KornbrustDJMacDonaldJSPeterCPToxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbitsJ Pharmacol Exp Ther198924824985052918466
   PubMed Web of Science ®Google Scholar
• FeleszkoWMlynarczukIBalkowiec-IskraEZLovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in miceClin Cancer Res2000652044205210815931
   PubMed Web of Science ®Google Scholar
• LishnerMBar-SefAElisAFabianIEffect of simvastatin alone and in combination with cytosine arabinoside on the proliferation of myeloid leukemia cell linesJ Investig Med2001494319324
   PubMedGoogle Scholar
• LeeJLeeIHanBEffect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutationsJ Natl Cancer Inst2011103867468821398618
   PubMed Web of Science ®Google Scholar
• XiaoHYangCSCombination regimen with statins and NSAIDs: a promising strategy for cancer chemopreventionInt J Cancer2008123598399018548583
   PubMed Web of Science ®Google Scholar
• MaronDJFazioSLintonMFCurrent perspectives on statinsCirculation2000101220721310637210
   PubMed Web of Science ®Google Scholar
• FarmerJATorre-AmioneGComparative tolerability of the HMG-CoA reductase inhibitorsDrug Safety200023319721311005703
   PubMed Web of Science ®Google Scholar
• NawarskasJJHMG-CoA reductase inhibitors and coenzyme Q10Cardiology Rev20051327679
   PubMedGoogle Scholar
• WilliamsDFeelyJPharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitorsClin Pharmacokinet200241534337012036392
   PubMed Web of Science ®Google Scholar
• MoldenEAnderssonKSSimvastatin-associated rhabdomyolysis after coadministration of macrolide antibiotics in two patientsPharmacotherapy200727460360717381388
   PubMed Web of Science ®Google Scholar
• BatchelorTTTaylorLPThalerHTPosnerJBDeAngelisLMSteroid myopathy in cancer patientsNeurology1997485123412389153449
   PubMedGoogle Scholar
• GopaluniSThomasLMShahCWhen myopathy strikes in a cancer patientGastrointest Cancer Res: GCR20093521221420084165
   PubMedGoogle Scholar
• TroyanovYLandon-CardinalOFritzlerMJAtorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotypeMedicine (Baltimore)2017963e569428099331
   PubMed Web of Science ®Google Scholar
• TellierPL’ezetimibe : de la pharmacologie aux essais thérapeutiques [Ezetimibe: from pharmacology to clinical trials]Ann Endocrinol (Paris)2003646442447 French15067249
   PubMedGoogle Scholar
• JeuLChengJWPharmacology and therapeutics of ezetimibe (SCH 58,235), a cholesterol-absorption inhibitorClin Ther20032592352238714604738
   PubMed Web of Science ®Google Scholar
• YatskarLFisherEASchwartzbardAEzetimibe: rationale and role in the management of hypercholesterolemiaClin Cardiol2006292525516506638
   PubMedGoogle Scholar
• FraunbergerPGroneEGroneHJDrexelHWalliAKEzetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigsJ Inflamm (London)201714328167864
   PubMedGoogle Scholar
• SakuraiTHigashitsujiHKashidaHThe oncoprotein gankyrin promotes the development of colitis-associated cancer through activation of STAT3Oncotarget2017815247622477628160571
   PubMedGoogle Scholar
• AssarafYGMolecular basis of antifolate resistanceCancer Metastasis Rev200726115318117333344
   PubMed Web of Science ®Google Scholar
• OronskyBTReidTKnoxSJScicinskiJJThe scarlet letter of alkylation: a mini review of selective alkylating agentsTransl Oncol20125422622922937173
   PubMedGoogle Scholar
• YaredJATkaczukKHUpdate on taxane development: new analogs and new formulationsDrug Des Devel Ther20126371384
   PubMed Web of Science ®Google Scholar
• BrownCTargeted therapy: an elusive cancer targetNature20165377620S106S10827626779
   PubMedGoogle Scholar
• WarburgOOn the origin of cancer cellsScience (New York, NY)19561233191309314
   Google Scholar
• BuchwaldHCholesterol inhibition, cancer, and chemotherapyLancet (London, England)1992339880211541156
   PubMedGoogle Scholar
• CruzPMMoHMcConathyWJSabnisNLackoAGThe role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeuticsFront Pharmacol2013411924093019
   PubMed Web of Science ®Google Scholar
• AuneDKeumNGiovannucciEWhole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studiesBMJ2016353i271627301975
   PubMed Web of Science ®Google Scholar
• ShiCZhangNFengYCaoJChenXLiuBAspirin inhibits IKK-beta-mediated prostate cancer cell invasion by targeting matrix metalloproteinase-9 and Urokinase-type plasminogen activatorCell Physiol Biochem20174141313132428278500
   PubMedGoogle Scholar
• JiangJLanYQZhangTThe in vitro effects of caffeine on viability, cycle cycle profiles, proliferation, and apoptosis of glioblastomasEur Rev Med Pharmacol Sci201519173201320726400523
   PubMedGoogle Scholar
• DongSKongJKongJLow concentration of caffeine inhibits the progression of the hepatocellular carcinoma via Akt signaling pathwayAnticancer Agents Med Chem201515448449225666502
   PubMedGoogle Scholar
• ChenYChouWCDingYMWuYCCaffeine inhibits migration in glioma cells through the ROCK-FAK pathwayCell Physiol Biochem20143361888189825011614
   PubMedGoogle Scholar
• LiuLLiuJDaiSReduced transthyretin expression in sera of lung cancerCancer Sci200798101617162417683510
   PubMed Web of Science ®Google Scholar
• NoyNLiLAbolaMVBergerNAIs retinol binding protein 4 a link between adiposity and cancer?Horm Mol Biol Clin Investig20152323946
   PubMedGoogle Scholar
• ZhaoCAnnamalaiLGuoCCirculating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancerNeoplasia2007911717325738
   PubMed Web of Science ®Google Scholar
• Zamanian-DaryoushMDiDonatoJAApolipoprotein A-I and cancerFront Pharmacol2015626526617517
   PubMed Web of Science ®Google Scholar
• MareeAOFitzgeraldDJAspirin and coronary artery diseaseThromb Haemost20049261175118115583721
   PubMedGoogle Scholar
• BarrettPJCaseyEKSisungCGaebler-SpiraDCaffeine as a neurostimulant: Two pediatric acquired brain injury casesJ Pediatr Rehabil Med20103322923221791853
   PubMedGoogle Scholar
• TazzeoTBatesGRomanHNCaffeine relaxes smooth muscle through actin depolymerizationAm J Physiol Lung Cell Mol Physiol20123034L334L34222683573
   PubMed Web of Science ®Google Scholar
• KolahdouzanMHamadehMJThe neuroprotective effects of caffeine in neurodegenerative diseasesCNS Neurosci Ther201723427229028317317
   PubMed Web of Science ®Google Scholar
• EngelhardtGMauzABPairetMRole of caffeine in combined analgesic drugs from the point of view of experimental pharmacologyArzneimittelforschung19974789179279296278
   PubMedGoogle Scholar
• PiniLAGuerzoniSCainazzoMCiccareseMPrudenzanoMPLivreaPComparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, cross-over studyJ Headache Pain201213866967523054063
   PubMed Web of Science ®Google Scholar
• CortezDCaffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinasesJ Biol Chem200327839371393714512847089
   PubMed Web of Science ®Google Scholar
• KimYMLeeEJParkSYChoKHKimJYPyoHCyclooxygenase-2 up-regulates ataxia telangiectasia and Rad3 related through extracellular signal-regulated kinase activationMol Cancer Res2009771158116819584262
   PubMedGoogle Scholar
• ZhuWDepamphilisMLSelective killing of cancer cells by suppression of geminin activityCancer Res200969114870487719487297
   PubMed Web of Science ®Google Scholar